Autolus Therapeutics plc (“Autolus”) announced on 6/22/2018 the pricing of its initial public offering in the United States of 8,823,530 American Depositary Shares (“ADSs”) representing 8,823,530 ordinary shares at an initial public offering price of $17.00 per ADS for total gross proceeds of approximately $150.0 million. All ADSs sold in the offering were offered by Autolus. The ADSs are expected to begin trading on The Nasdaq Global Select Market on June 22, 2018 under the ticker symbol “AUTL.”  In addition, Autolus has granted the underwriters a 30-day option to purchase up to an additional 1,323,529 ADSs at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on June 26, 2018, subject to customary closing conditions.

Goldman Sachs & Co. LLC and Jefferies LLC are acting as joint book-running managers for the offering. Wells Fargo Securities, LLC and William Blair & Company, L.L.C. are acting as lead managers.

Autolus is developing cell programming technologies and specialised manufacturing processes to develop programmed T cell product candidates to treat cancer. Their technology uses Chimeric Antigen Receptors (CARs) or T-cell receptors (TCRs) to reprogramme T cells to recognise and kill the tumour cell. The company has developed technologies to modulate T cell activity or eliminate programmed T cells in the event of severe side effects that have been observed with these types of therapies.